Available in United States, Brazil
This is a multicenter, randomized, double-blind, placebo controlled, parallel group study
designed to evaluate the efficacy and safety of dexpramipexole in adults and adolescents
with severe, inadequately controlled asthma with eosinophilic phenotype on medium to
high-dose inhaled corticosteroids (ICS )and at least one additional asthma controller
medication with or without oral corticosteroids (OCS). Approximately 1400 participants
will be randomized globally. Participants will receive dexpramipexole, or placebo,
administered orally, over a 52-week treatment period. The study also includes a
post-treatment follow-up period of 4 weeks.
1395Patients around the world